Research Article
Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia
Table 3
Summary of characterization carried out for each iPSC line.
| | iPSC line | Cytometry analysis | qPCR pluripotency | Pluripotency immunocytochemistry | EB formation/qPCR | Teratoma formation | IHQ analysis | HE analysis | Scorecard |
| | PBscd01 | OCT4/NANOG/SOX2 | OCT4/NANOG/SOX2 | OCT4/NANOG/SOX2 | NESTIN/α-SMA/α-FETO | FORMED | ECTO/MESO/ENDO | STAINED | CARRIED OUT | | PBscd02 | OCT4/NANOG/SOX2 | NO | NO | NO | FORMED | NO | STAINED | NO | | PBscd03 | OCT4/NANOG/SOX2 | NO | NO | EB FORMATION | FORMED | NO | STAINED | NO | | PBscd08cl02HU | OCT4/NANOG/SOX2/SSEA4 | NO | NO | EB FORMATION | FORMED | ECTO/MESO/ENDO | STAINED | NO | | PBscd08cl03HU | OCT4/NANOG/SOX2/SSEA4 | NO | NO | NO | NO | NO | NO | NO | | PBscd08cl04HU | OCT4/NANOG/SOX2/SSEA4 | NO | NO | NO | INJECTED | NO | NO | NO |
|
|
PB: peripheral blood; scd: sickle cell disease; HU: hydroxyurea; EB: embryoid body; α-SMA: alpha-smooth muscle actin; α-FETO: alpha-fetoprotein; IHQ: immunohistochemistry; ECTO: ectoderm; MESO: mesoderm; ENDO: endoderm; HE: hematoxylin and eosin.
|
